Licciardi, PV; Toh, ZQ; Dunne, E; Wong, SS; Mulholland, EK; Tang, M; Robins-Browne, RM; Satzke, C (2012) Protecting against pneumococcal disease: critical interactions between probiotics and the airway microbiome. PLoS pathogens, 8 (6). e1002652. ISSN 1553-7366 DOI: https://doi.org/10.1371/journal.ppat.1002652

Downloaded from: http://researchonline.lshtm.ac.uk/1098187/

DOI: 10.1371/journal.ppat.1002652

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by/2.5/
Protecting against Pneumococcal Disease: Critical Interactions between Probiotics and the Airway Microbiome

Paul V. Licciardi1,2*, Zheng Quan Toh3, Eileen Dunne1, Sook-San Wong4, Edward K. Mulholland3,4, Mimi Tang2,5,6, Roy M. Robins-Browne7,8, Catherine Satzke1,7,8

1 Pneumococcal Research, Murdoch Childrens Research Institute, Royal Children’s Hospital, Melbourne, Australia, 2 Allergy and Immune Disorders, Murdoch Childrens Research Institute, Royal Children’s Hospital, Melbourne, Australia, 3 London School of Hygiene and Tropical Medicine, London, United Kingdom, 4 Menzies School of Health Research, Darwin, Australia, 5 Allergy and Immunology, Royal Children’s Hospital, Melbourne, Australia, 6 Department of Paediatrics, The University of Melbourne, Melbourne, Australia, 7 Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Australia, 8 Infectious Diseases and Microbiology, Murdoch Childrens Research Institute, Royal Children’s Hospital, Melbourne, Australia

Streptococcus pneumoniae (the pneumococcus) is a predominant cause of pneumonia, meningitis, and bacteremia. It is a leading killer of children under 5 years of age, responsible for the deaths of up to 2 million children annually [1]. Most deaths occur in African and Asian developing countries; however, pneumococcal disease is also a significant problem in particular populations of developed countries, such as the North American Indians, and indigenous Alaskans and Australians [1–3]. Although vaccination is the most cost-effective method of protection against pneumococcal disease, cost remains a barrier, as does vaccine delivery and efficacy. In this opinion piece, we discuss the potential complementary role of probiotics to vaccines in preventing pneumococcal disease through targeting the microbiome of the upper respiratory tract.

A prerequisite for pneumococcal disease is adherence of the bacterium to host nasopharyngeal epithelium leading to colonization (carriage). The mucosal surface and the microbiome of the nasopharynx are thought to protect against carriage [4]. Vaccination with pneumococcal vaccines reduces carriage of the organism, and the risk of invasive disease caused by vaccine serotypes and some cross-reactive non-vaccine serotypes. Moreover, vaccines generate herd immunity that may protect unvaccinated individuals against infection [5].

In North America and other developed regions, >80% of pediatric invasive pneumococcal disease (IPD) is accounted for by serotypes contained within the first-generation seven serotype conjugate vaccine (PCV7, Prevnar, Wyeth/Pfizer, United States). In high-risk populations, several factors diminish the efficacy of pneumococcal vaccines. For example, PCV7 protects against only ~50% of serotypes causing IPD in developing countries of Africa and Asia [6]. Pneumococcal conjugate vaccines are also too expensive for resource-poor countries that experience the overwhelming burden of disease globally. The GAVI Alliance has made significant inroads to this problem, providing access to these and other life-saving vaccines to children most in need at a cost of US$1 billion per year [7]. Nevertheless, complete vaccine delivery is another major public health challenge. While GAVI is planning to implement pneumococcal conjugate vaccines in 19 developing countries over the next 2 years [8], vaccine uptake may be more difficult in certain populations. Amongst indigenous Australians, <50% of infants aged 7 months have received the full three-dose schedule (at 2, 4, and 6 months) [9], providing suboptimal protection against colonization and disease. In many countries, the first PCV7 dose is received after colonization has occurred—usually within the first 6 weeks of life—which may further limit the efficacy of pneumococcal vaccination.

Furthermore, serotype replacement is considered the most significant problem in the post-PCV7 era. Elimination of vaccine-serotype carriage has provided new niches for colonization and subsequent rises in invasive disease with non-PCV7 serotypes [10]. Although licensure of higher valency PCVs containing ten or 13 serotypes would be expected to reduce serotype replacement, the emergence of other invasive serotypes is likely.

Other early life strategies to prevent pneumococcal disease are needed, particularly for resource-poor settings. Maternal and neonatal immunization approaches are currently under investigation for their impact on disease during the first weeks of life. Targeting the microbiome to modulate colonization has been postulated as one mechanism to improve the efficacy of a range of vaccines against multiple pathogens [11]. It has now been demonstrated that in early infancy, colonization with pneumococci prior to conjugate vaccination causes impaired immune responses to the carried serotype [12,13]. Exploiting the beneficial effects of probiotics on microbial colonization and immunity represents a novel approach to prevent or reduce pneumococcal colonization and disease.

The World Health Organization (WHO) defines probiotics as live micro-
organisms that confer a health benefit to the host and are generally regarded as safe in humans [14]. Moreover, clinical studies have confirmed the safety and feasibility of oral administration of probiotics in infancy [15,16]. *Lactobacillus* and *Bifidobacterium* are the two most widely studied genera of probiotic bacteria [17]. Probiotic activity is highly species- and strain-specific [18,19]. Principal amongst their pleiotropic effects is the capacity to counteract microbiome disturbances, suggesting the potential to modulate pneumococcal colonization [20]. Indeed, experimental data suggest that probiotics can influence the profile of microbial species in the nasopharynx to reduce pneumococcal colonization [21–24]. Probiotics also maintain epithelial barrier integrity and modulate systemic and mucosal immune responses [14]. Furthermore, probiotic-microbiome crosstalk is important, as intestinal microbiota can shape immune responses by controlling the relative activity of regulatory T cells and Th17 cells [25,26]. A paradigm for the effects of probiotics in modulating host responses in the nasopharynx to protect against pneumococcal infection is proposed in Figure 1. Importantly, while the mechanisms of action proposed are largely supported by animal studies, more research is needed to confirm these effects in humans.

Probiotics show specificity in their effect on microbial patterns in the nasopharynx. Most of the available data is based on animal models of colonization or disease. For example, in a mouse model of pneumococcal pneumonia, *Lactobacillus lactis* lowered lung colonization and increased specific IgG and IgA levels in bronchoalveolar secretions after challenge with pneumococcal serotype 14 [21], while *Lactobacillus fermentum* reduced nasopharyngeal colonization after challenge with pneumococcal serotype 6A [22]. In humans, the potential for probiotics to have an impact on airway microbial colonization is less clear. In 108 adult volunteers given a probiotic yogurt containing *Lactobacillus rhamnosus* GG (LGG), *Bifidobacterium* sp. B420, *Lactobacillus acidophilus* 145, and *Streptococcus thermophilus*, a significant reduction in pathogenic bacteria (including *Staphylococcus aureus*, *S. pneumoniae*, beta-hemolytic streptococci, and *Haemophilus influenzae*) was observed compared to a standard yogurt [24]. *Streptococcus salivarius* is suggested to be an appropriate probiotic species given that it is a known colonizer of the upper respiratory tract in humans [27]. It has been shown to produce bacteriocin-like substances with inhibitory activities against a number of important airway pathogens in vitro and in vivo [27,28] as well as possess immunomodulatory properties in vitro [29,30]. In otitis media-prone children given antibiotics prior to oral treatment with a powdered *S. salivarius* K12 formula, 33% were newly colonized with K12 while two of 19 children were shown to expand the pre-existing *S. salivarius* population [31]. No impact on clinical outcomes was reported in this study, and the small sample size used makes it difficult to draw meaningful conclusions. In contrast, when otitis-prone children (n = 155) were given a daily probiotic mix containing LGG, *L. rhamnosus* LC705, *B. breve* 99, and *Propionibacterium freudenreichii* JS [22] for 24 weeks, no effect on nasopharyngeal carriage of otitis pathogens was observed. Furthermore, this probiotic formula did not prevent the occurrence of otitis media in these children, although there was a trend of reduced recurrent respiratory infections [32]. Taken together, the evidence of probiotic effects in human studies is more limited compared to animal models and justifies the continued investigation of candidate probiotic species such as *S. salivarius* and lactobacilli on airway microbiotal colonization and their mechanisms of action.

To date, the effect of probiotics on the gastrointestinal microbiome have provided the best evidence for host-microbe interactions such as pathogen exclusion, enhanced mucus secretion, production of anti-bacterial factors, and modulation of host immunity [14]. Probiotics can restore aberrant microbiota patterns associated with inflammatory diseases such as Crohn’s Disease [33] and allergy [17]. Several clinical studies have shown that infants who later develop atopic dermatitis have altered microbiota, with greater numbers of pathogenic clostridial and staphylococcal species and fewer beneficial bifidobacteria [34,35]. Importantly, dysbiosis precedes clinical symptoms of allergy [36], indicating a causal relationship between altered microbiota and disease. Administration of LGG modulates the composition of the intestinal microbiota in allergic infants, and reduced by half the incidence of atopic dermatitis in high-risk infants by age 2 [36,37]. LGG also corrected dysbiosis and reduced disease severity in a mouse model of colitis [38].

These data have implications for pneumococcal disease. Importantly, lung immunity is affected by the intestinal microbiome, which induces Th1 and IgA responses via specific inflammasomes [39]. Therefore, modulation of inflammasome activity by probiotics represents a key biological target. The balance between microbiome status and health are also linked to the production of potent anti-inflammatory short-chain fatty acids such as butyrate and acetate [40]. Probiotics restore short-chain fatty acid levels, and the protective effects of *Bifidobacteria* species against enterohemorrhagic *E. coli* infection was shown to be dependent on acetate production [41].

Probiotics also appear to play an important role in facilitating mucosal immunity against infection [42]. Specifically, probiotics are demonstrated to be effective vaccine adjuvants, enhancing IgG- and IgA-specific responses to parenteral and mucosal vaccines such as influenza [43], *H. influenzae* type b (Hib) [44], polio [45], rotavirus [46], and *Salmonella typhi* [47] in humans. More studies on the adjuvant properties of probiotics in humans are needed, as the effects reported are often variable and have been based on clinical trials involving small sample sizes. For example, in the study by Fang et al. [47], treatment with LGG or *L. lactis* did not significantly enhance the IgG or IgA response to an oral *S. typhi* Ty21a vaccine despite LGG increasing *S. typhi*-specific IgA antibody secreting cells in a greater number of subjects than *L. lactis* or placebo. Similarly, while supplementation with a *Bifidobacterium longum* BL999 and *L. rhamnosus* LPR mix to infants doubled the anti-HBsAg IgG levels following vaccination compared to placebo, this was not statistically significant [48]. In a study by Kukkonen et al. [44], daily administration of a LGG, *L. rhamnosus* LC705, *B. breve* Bi89, and *Propionibacterium freudenreichii* combination to mothers in the last 4 weeks of pregnancy, and to their infants for the first 6 months of life, increased the Hib-specific IgG response in infants. However, no change in diphtheria toxoid or tetanus toxoid IgG levels was observed, suggesting that the effects of probiotics may vary depending on the vaccine antigen used. Recently, *Lactobacillus casei* was reported to significantly enhance the pneumococcal protective protein A (PpA)-specific IgG and IgA response in the serum and mucosa following nasal vaccination with PpA and was associated with a significantly reduced pathogen load in the nasal lavage by day 42 post-immunization [42]. Despite this, the adjuvant activity of probiotics following pneumococcal vaccination in humans is
unknown and remains an intriguing prospect for further research.

The promising findings of these studies has made it increasingly clear that significant research emphasis on reducing pneumococcal colonization during the neonatal period is warranted, ideally involving human clinical trials. Novel early life strategies that reduce infection with S. pneumoniae may have important health benefits, especially in high-risk populations. The combined effects of modulating the nasopharyngeal microbiome and enhanced mucosal immunity justify the continued investigation of probiotics for protection against pneumococcal infection.

Acknowledgments

We thank Thanh Dang for the artwork in Figure 1, and Eleanor Neal for helpful review of the manuscript.


